富血小板血浆联合氨甲环酸治疗黄褐斑疗效观察

目的 探讨富血小板血浆(PRP)联合氨甲环酸片治疗黄褐斑的临床疗效及安全性.方法 将入选的79例患者随机分为两组,对照组(39例)单纯口服氨甲环酸片治疗,疗程为3个月,治疗组(40例)在对照组基础上,联合PRP治疗,每月1次,共3次.治疗结束后比较两组临床疗效及不良反应,6个月后观察复发情况.结果 3个月后,治疗组和对...     

氨甲环酸不同给药途径治疗黄褐斑的疗效观察

黄褐斑是一种发生于面部的获得性色素沉着性皮肤病,好发于育龄期女性。发病与内分泌、遗传、日光、自由基、局部微生态、化妆品、精神因素等有关［１］,严重影响患者容貌及身心健康。目前黄褐斑的治疗均不理想,有报道用口服氨甲环酸治疗黄褐斑已取得较好的临床效果［2-3］。我们尝试采用氨甲环酸不同给药途径对黄褐斑患者进行治疗,探讨其临床疗效……     

超声导入氨甲环酸联合谷胱甘肽治疗黄褐斑的疗效观察

目的：探讨超声导入氨甲环酸联合谷胱甘肽治疗黄褐斑的疗效及安全性。方法：130例黄褐斑患者随机分为治疗组、对照1组和对照2组,治疗组48例采用超声导入氨甲环酸联合谷胱甘肽治疗;对照1组42例采用超声导入氨甲环酸治疗;对照2组40例采用谷胱甘肽静滴治疗;三组患者总疗程为12周。治疗结束后比较三组总有效率。结果：治疗4周及12周后,治疗组、对照1组及对照2组患者总有效率分别为68.75％、47.62％、40.00％和89.58％、80.95％、60.00％。治疗组在治疗4周后总有效率明显高于对照1组及对照2组（礸2＝4.13,P＝0.042;礸2＝7.31,P＝0.007）;治疗组在治疗12周后的总有效率明显高于对照2组（礸2＝9.11,P＝0.003）,但与对照1组总有效率的差异无统计学意义（礸2＝1.35,P＝0.245）。结论：超声导入氨甲环酸联合谷胱甘肽治疗黄褐斑起效较快,无明显不良反应。     

氨甲环酸治疗黄褐斑的研究进展

氨甲环酸可以通过多个环节治疗黄褐斑,包括抑制真皮血管形成,减少肥大细胞数目并抑制其活性,减少基底膜带损伤,抑制表皮黑素合成和转运,促进皮肤屏障功能恢复等。本文综述氨甲环酸治疗黄褐斑的机制及疗效,为临床应用提供更多依据。     

氨甲环酸联合化斑汤治疗黄褐斑的临床研究

黄褐斑是一种常见的获得性色素沉着性皮肤病。我院自2002年—2005年以来,应用氨甲环酸加化斑汤治疗黄褐斑,取得了一定的疗效,现报告如下。1资料与方法1.1一般资料黄褐斑患者142例,均来源于我科门诊的患者,不伴有严重的心脑血管、肝肾、胃肠和造血系统等疾病。142例随机分为两组     

氨甲环酸片联合Q开关YAG激光治疗黄褐斑疗效观察

目的:观察氨甲环酸片联合Q开关YAG激光对黄褐斑的治疗效果。方法:选取2006年3月～2011年3月间在我院确诊的黄褐斑患者(150例)为研究对象,随机分为治疗组和对照组,治疗组采用氨甲环酸片加Q开关YAG激光治疗,对照组仅予以Q开关YAG激光治疗,两组均同时辅以中药面膜外敷。治疗3～12个月,随访6～12个月,观察治疗后的临床效果、复发及不良反应等情况,对结果进行统计分析。结果:治疗组有效率为82.2%,对照组为61.67%,治疗组较对照组对面部色斑治疗占明显优势(P=0.014),并未见不良反应。结论:氨甲环酸片联合Q开关YAG激光治疗面部黄褐斑疗效好,适合临床应用。     

氨甲环酸片联合Q开关YAG激光治疗黄褐斑疗效观察

目的：观察氨甲环酸片联合Q开关YAG激光对黄褐斑的治疗效果。方法：选取2006年3月～2011年3月间在我院确诊的黄褐斑患者（150例）为研究对象,随机分为治疗组和对照组,治疗组采用氨甲环酸片加Q开关YAG激光治疗,对照组仅予以Q开关YAG激光治疗,两组均同时辅以中药面膜外敷。治疗3～12个月,随访6～12个月,观察治疗后的临床效果、复发及不良反应等情况,对结果进行统计分析。结果：治疗组有效率为82.2%,对照组为61.67%,治疗组较对照组对面部色斑治疗占明显优势（P=0.014）,并未见不良反应。结论：氨甲环酸片联合Q开关YAG激光治疗面部黄褐斑疗效好,适合临床应用。     

扶正化瘀胶囊联合氨甲环酸治疗黄褐斑的临床观察

目的观察扶正化瘀胶囊联合氨甲环酸治疗黄褐斑的临床疗效及安全性。方法 78例黄褐斑患者随机分为2组,治疗组40例:口服扶正化瘀胶囊,3粒/次,3次/d,氨甲环酸,0.25 g/次,2次/d;对照组38例,单用氨甲环酸,0.25g/次,2次/d。经过12周治疗后观察疗效及不良反应。结果治疗组基本治愈率20%,有效率90%;对照组基本治愈率10.5%,有效率71.1%,2组有效率差异有统计学意义(P0.005)。对照组中月经量减少者28例、治疗组仅2例。结论联合中药制剂扶正化瘀胶囊可提高氨甲环酸治疗黄褐斑的临床疗效及安全性。     

微针疗法配合氨甲环酸湿敷治疗黄褐斑的疗效分析

目的观察微针疗法联合氨甲环酸湿敷治疗黄褐斑的效果。方法在我院2018年6月~2019年5月收治的黄褐斑患者中选出82例为观察对象,随机分成两组,对照组患者采用氨甲环酸片口服治疗,观察组患者采用微针疗法联合氨甲环酸湿敷治疗,对比两组的治疗效果。结果治疗6个月后,观察组治疗总有效率97.56%高于对照组治疗总有效率82.93%,P <0.05;治疗6个月后的黄褐斑评分比较:观察组低于对照组,P <0.05;观察组患者不良反应发生率与对照组差异不明显,P> 0.05,两组不良反应均未影响治疗进程。结论微针疗法与氨甲环酸湿敷结合应用于黄褐斑治疗效果确切,有助于促进皮损消退,且安全性高,值得推广。     

Q开关1064nm激光联合口服氨甲环酸片治疗黄褐斑的疗效及安全性探讨

目的 观察氨甲环酸片联合Q开关1 064nm激光治疗黄褐斑的疗效及安全性.方法 选取2017年3月至2019年12月在某医院皮肤科接受治疗的80例黄褐斑患者作为研究对象,随机分为两组:观察组40例患者实施Q开关1 064nm激光联合氨甲环酸片治疗;对照组40例患者单独实施Q开关1 064nm激光治疗.比较两组患者治疗前...     

Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial

Background

Melasma is a hyperpigmentary disorder causing cosmetic disfigurement. We aimed to compare the efficacy and safety of tranexamic acid (TXA) microinjections with TXA mesoneedling for facial melasma.

Methods

This randomized assessor-blind split-face controlled trial included patients with symmetric facial melasma. One side of the face received TXA (100 mg/ml) mesoneedling and the other side intradermal TXA microinjections. The interventions were repeated three times with 4-week intervals (weeks 0, 4, and 8). The primary outcome was improvement in modified Melasma Area and Severity Index (mMASI) 4 weeks after the final treatment session. Secondary outcomes were complications and patient satisfaction with the treatments evaluated by a visual analog scale (VAS).

Results

All 27 patients included in the study were female (mean age: 44.22 ± 8.39 years). Both groups were comparable in terms of mMASI scores before and after treatment (standardized mean difference [SMD] = 0.32, 95% confidence interval [CI] −0.22; 0.85, p = 0.248 and SMD = −0.13, 95% CI −0.66; 0.40, p = 0.633, respectively). The mMASI score change from baseline was not different (SMD = −0.39, 95% CI −0.93; 0.15, p = 0.157). However, patient satisfaction was significantly higher with TXA mesoneedling (SMD = 0.77, 95% CI 0.21; 1.32, p = 0.007). Post-inflammatory hyperpigmentation occurred in one patient in the TXA mesoneedling group. Erythema, scaling, and edema were significantly higher with TXA mesoneedling (p < 0.001).

Conclusions

TXA mesoneedling was comparable with TXA microinjection in the treatment of facial melasma, while patient satisfaction was significantly higher with TXA mesoneedling; however, the high frequency of complications occurring with this treatment should be taken into account.     

氨甲环酸在皮肤科的应用进展

氨甲环酸是一种常见的抗纤溶药物,目前广泛用于血友病患者拔牙术后止血、其他外科手术或急性创伤止血、月经过多等疾病.越来越多地研究表明它不仅具有抗继发性纤溶作用,还具有抑制血管生成、减少黑色素生成、抗炎、抗变态反应、抗皮肤自然衰老和光老化作用.在皮肤科领域,氨甲环酸对黄褐斑、炎症后色素沉着、Riehl黑变病等多种疾病具有治...     

Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies

Melasma is a human melanogenesis dysfunction that results in localized, chronic acquired hyperpigmentation of the skin. It has a significant impact on appearance, causing psychosocial and emotional distress, and reducing the quality of life of the affected patients. Tranexamic acid (TA) is a plasmin inhibitor used to prevent abnormal fibrinolysis to reduce blood loss and exerts its effect by reversibly blocking lysine binding sites on plasminogen molecules, thus inhibiting plasminogen activator (PA) from converting plasminogen to plasmin. As plasminogen also exists in human epidermal basal cells and cultured human keratinocyte are known to produce PA, there is basic rationale that TA will affect keratinocyte function and interaction. A thorough literature review indicates that while TA is used through various route of administration including oral, topical, and intradermal injection and as adjutant therapy with laser to treat melasma, its efficacy is not established adequately. Further studies are needed to clarify the role of TA in treatment of melasma.